# ClinicalTrials.gov record NCT06851962

> PeptideScanner retained ClinicalTrials.gov record NCT06851962 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was dulaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06851962-dulaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-04
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06851962-dulaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06851962-dulaglutide-v1.json
- Content SHA-256: `f57b4bb016cab255b86e05d3137fa28c6d7d9d3217d5c984a6693d723eddab51`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT06851962 ([`ctg-observation-nct06851962-2026-09-04-0385163138fd`](#source-ctg-observation-nct06851962-2026-09-04-0385163138fd))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06851962 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct06851962-2026-09-04-0385163138fd`](#source-ctg-observation-nct06851962-2026-09-04-0385163138fd))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06851962 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was dulaglutide. ([`ctg-observation-nct06851962-2026-09-04-0385163138fd`](#source-ctg-observation-nct06851962-2026-09-04-0385163138fd))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06851962-2026-09-04-0385163138fd`](#source-ctg-observation-nct06851962-2026-09-04-0385163138fd))

## Sources

<a id="source-ctg-observation-nct06851962-2026-09-04-0385163138fd"></a>
- **ClinicalTrials.gov record NCT06851962 · retained source version 2026-09-04:0385163138fd0b6137377c4b641f3184e88dae54c1363736b4830b61c27d2cb3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06851962) (`ctg-observation-nct06851962-2026-09-04-0385163138fd`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06851962." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06851962-dulaglutide-v1.json SHA-256: f57b4bb016cab255b86e05d3137fa28c6d7d9d3217d5c984a6693d723eddab51.